US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Halting Neurodegeneration as Leading Treatment Priority
According to Spherix Global Insights’ first market landscape study on Huntington’s disease, neurologists are staking their hopes on gene therapy. EXTON, Pa., January 3, 2024 – Huntington’s disease (HD) could be called the perfect storm of neurodegenerative diseases. It causes a loss of critical striatal neurons which affect not only motor function – causing symptoms […]
Majority of Dermatologists in US Prescribe Baricitinib to Patients With Alopecia Areata, Report Shows
Bariticinib (Olumiant; Eli Lilly) is prescribed by the majority of US dermatologists to their patients with alopecia areata (AA), according to a recent analysis (Market Dynamix: Alopecia Areata). Additionally, more than half of US dermatologists have begun trial of ritlecitinib (Litfulo; Pfizer) in their patients with AA. According to the analysis, 6-month market projections for […]
Survey finds neurologists seek to minimize side effects of treatment in Parkinson’s
Fewer than half of those dealing with Parkinson’s disease in the United States are able to gain clinical control of symptoms without experiencing side effects, according to results of a new study. Spherix Global engaged its initial Insights’ Market Dynamix to canvas more than 100 neurologists, employing a combination of quantitative survey and qualitative interview […]
US Gastroenterologist Projections Suggest Significant Shift in Ulcerative Colitis Landscape Afoot, with Launches of Eli Lilly’s Omvoh, Pfizer’s Velsipity, Takeda’s Subcutaneous Entyvio, and Celltrion’s Zymfentra
Prior to launch, prescribers estimate that TNF inhibitors are likely to bear the greatest brunt of increased adoption of the newest market entrants, according to Spherix Global Insights [Exton PA, November 13, 2023] — In the past two months, the landscape of available treatments for ulcerative colitis (UC) has undergone a significant expansion, marked by […]
Survey shows limited uptake with new anemia drugs
PHILADELPHIA — Results of a survey conducted in the U.S. and abroad showed that most nephrologists remain wary about prescribing hypoxia-inducible factor-prolyl hydroxylase inhibitors, according to a poster presentation at ASN Kidney Week. The survey was distributed to 207 U.S. and 208 European nephrologists practicing in Germany, Italy, France, Spain and the United Kingdom with […]
Pfizer and AbbVie oral migraine drugs earn top spots with physicians, survey finds
Oral drugs have raced to the front of the pack in the crowded migraine therapy space and appear to be staying put with physicians. Primary care physicians in particular are prescribing Pfizer’s Nurtec and AbbVie’s Ubrelvy and Qulipta, according to Spherix Global Insights’ latest quarterly survey of migraine drug prescribers. Primary docs reported more than […]
In a Push to Limit Use of Glucocorticoids, US and EU5 Rheumatologists are Increasingly Turning to GSK’s Benlysta and AstraZeneca’s Saphnelo for the Treatment of Moderate-to-Severe Systemic Lupus Erythematosus, According to Spherix Global Insights
Despite overall biologic growth in both geographies, use of advanced systemic treatments in the US outpaces the EU5. EXTON, PA., October 4, 2023 – Prior to the initial approval of Benlysta in 2011, systemic lupus erythematosus (SLE) patients and prescribers had limited options for the management of this debilitating disease, often relying on symptom management […]
Consecutive Use of TNF-Inhibitors for the Treatment of Psoriatic Arthritis at Lowest Point Recorded, as Use of Biologics with Alternate Mechanisms of Actions Continue to Grow, According to Spherix Global Insights
Analysis of 1,025 recently switched PsA patients reveals second- or later-line usage of IL-17, IL-23, and JAK inhibitors growing in popularity. Exton PA, October 3, 2023 — US rheumatologists (n=204) report nearly two-thirds of their psoriatic arthritis (PsA) patients are undergoing treatment with advanced systemic therapies. What’s more, one-third of these patients have switched therapies […]
Survey Reveals Adalimumab-atto Maintains Leadership in US Adalimumab Biosimilars Market
Spherix Global Insights, a leading provider of market research, conducted a survey using a sample of 81 rheumatologists, 83 gastroenterologists, and 80 dermatologists to evaluate adoption rates, experiences, concerns, and future expectations of biosimilars.
Amgen tipped to keep Otezla market share in fight with BMS’ Sotyktu, leaving opportunity for J&J
Amgen’s $13.4 billion Otezla bet can withstand competition from Bristol Myers Squibb’s Sotyktu. That is the conclusion of analysts at Spherix Global Insights, who found Amgen is holding on to its market share and largely limiting BMS’ growth to the conversion of users of injectable biologics. BMS sold Otezla to Amgen to secure regulatory clearance for […]
